Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

Older chronic lymphocytic leukemia patients have poor outcomes with standard treatments and are underrepresented in clinical trials. We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (≥70 and <70 years) treated with single-agent flavopi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stephens, Deborah M., Ruppert, Amy S., Blum, Kristie, Jones, Jeffrey, Flynn, Joseph M., Johnson, Amy J., Ji, Jia, Phelps, Mitch A., Grever, Michael R., Byrd, John C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2012
Témata:
Original Articles and Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291598/
https://ncbi.nlm.nih.gov/pubmed/22271900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.047324
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky